Plat

(redirected from tissue plasminogen activator)
Also found in: Dictionary, Thesaurus, Medical, Financial, Acronyms, Encyclopedia, Wikipedia.
Related to tissue plasminogen activator: streptokinase

Plat

A map of a town or a section of land that has been subdivided into lots showing the location and boundaries of individual parcels with the streets, alleys, easements, and rights of use over the land of another.

A plat is usually drawn to scale.

See: intertwine, land, plot

PLAT. A map of a piece of land, in which are marked the courses and distances of the different lines, and the quantity of land it contains.
     2. Such a plat;nay be given in evidence in ascertaining the position of the land, and what is included, and may serve to settle the figure of a survey, and correct mistakes. 5 Monr. 160. See 17 Mass. 211; 5 Greenl. 219; 7 Greenl, 61; 4 Wheat. 444; 14 Mass. 149.

References in periodicals archive ?
Utilization of intravenous tissue plasminogen activator for acute ischemic stroke.
Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (> or =80 years) stroke patients.
Treatment of intraventricular hemorrhage with tissue plasminogen activator.
Cyclic AMP potentiates phorbol ester stimulation of tissue plasminogen activator release and inhibits secretion of plasminogen activator inhibitor-1 from human endothelial cells.
Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction, N Engl J Med, 1995, 332:1418-24.
Wallis and Lahri alluded to possible collusion between Genentech, which manufactures tissue plasminogen activator (tPA) in the USA, and the American Heart/ Stroke Association concerning their recommendation for use of IVI tPA in their stroke guideline and by implication the Food and Drug Administration (FDA) approval of the use of tPA for acute ischaemic stroke.
The advent of tissue plasminogen activator (tPA) has provided an important treatment option for this devastating event, tPA converts plasminogen to plasmin, which is then able to break down fibrin in clots (Vallerand & Deglin, 2001).
A powerful drug called tPA, or tissue plasminogen activator, can dissolve these clots.
If further study confirms the value of UCH-L1 as the first clinical biomarker in traumatic brain injury (TBI), physicians will be better able to identify targets for drug therapy and guide the timing of treatment with such agents as tissue plasminogen activator, she explained.
Treatment with tissue plasminogen activator (TPA) was used in 18 patients, of whom 3 (17%) subsequently had an intracerebral hemorrhage.